Shahrokh F. Shariat

Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, USA.

Dr. Shariat is currently professor and chairman of the department of urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. He is also adjunct professor of urology and medical oncology at Weill Cornell Medical Center, New York, NY and adjunct professor of urology at the University of Texas Southwestern Medical Center, Dallas, TX, USA. He has published more than 699 peer-reviewed research papers (h-index: 62; total number of citations: 16320), 84 non-peer-reviewed research papers, and a dozen book chapters, is the holder of four patents stemming from his research into prostate and bladder cancer, and is the recipient of various national and international rewards. He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma Collaboration) and prospective clinical trials. He is a member of various academic societies and a journal, meeting abstract,  and grant reviewer for numerous national and international organizations. He is  an  editorial  board  member of various journals including European Urology, BJU International, World Journal of Urology, Current Opinion in Urology, Immunotherapy, and Journal of Men's Health among others. His research focuses on urologic oncology - molecular mechanisms, markers, early detection, natural history,  treatment, translational and outcomes research. Specially, Dr. Shariat has been working on the discovery, testing, and validation of molecular markers associated with the biological and clinical behavior  of  prostate and urothelial cancers. His laboratory research focuses on integrative genomics and epigenomics  of urothelial carcinoma with the goal of designing personalized therapeutic strategies.

Focused Issue: Urothelial Carcinoma.